Categories
Change Password!
Reset Password!
This retrospective analysis compared the rates of eradication of non-bismuth concomitant quadruple therapy comprising of either esomeprazole and lansoprazole for first-line anti-H. pylori treatment.
A seven-day concomitant treatment (non-bismuth concomitant
quadruple therapy) with either esomeprazole or lansoprazole showed comparable
rates of eradication in H.pylori infected patients. Also, the
eradications were possibly affected by metronidazole-resistant
strains.
This retrospective analysis compared the rates of
eradication of non-bismuth concomitant quadruple therapy comprising of either
esomeprazole and lansoprazole for first-line anti-H.
pylori treatment.
In total, 206 H. pylori-infected patients were enrolled and assigned
into two groups based on esomeprazole and lansoprazole
based concomitant therapies
as:
After 8 weeks, patients were asked
to carry out urea breath tests.
Rates of eradication in the EACM group and LACM group in intention-to-treat (ITT) and the per-protocol (PP) analysis is depicted in the following table:
Patients in the LACM group
displayed more diarrhea compared to the EACM group (7.1% vs. 1.0%), however,
all were mild symptoms. Metronidazole resistance was the clinical feature
influencing the eradications as per the univariate analysis. Furthermore, a
trend was witnessed in dual metronidazole- and clarithromycin-resistant
strains.
Non-bismuth
concomitant quadruple therapy with either esomeprazole or lansoprazole provided similar outcomes concerning eradication rates for first-line
therapy for H. pylori. In the PP analysis, both groups could attain more
than 90% elimination of H. pylori.
Infection and Disease resistance
Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
Kuo-Tung Hung al.
Comments (0)